Edge Therapeutics, Inc. (NASDAQ:EDGE) insider Brian A. Leuthner sold 7,500 shares of Edge Therapeutics stock in a transaction that occurred on Friday, November 3rd. The stock was sold at an average price of $10.91, for a total value of $81,825.00. Following the completion of the sale, the insider now owns 102,736 shares of the company’s stock, valued at $1,120,849.76. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Edge Therapeutics, Inc. (NASDAQ:EDGE) traded up $0.02 during midday trading on Friday, hitting $10.75. The stock had a trading volume of 60,964 shares, compared to its average volume of 54,795. The company has a current ratio of 8.34, a quick ratio of 9.43 and a debt-to-equity ratio of 0.20.

Edge Therapeutics (NASDAQ:EDGE) last released its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported ($0.37) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.48) by $0.11. sell-side analysts expect that Edge Therapeutics, Inc. will post -1.9 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This article was originally posted by American Banking News and is the property of of American Banking News. If you are reading this article on another domain, it was stolen and republished in violation of United States and international copyright and trademark law. The original version of this article can be read at https://www.americanbankingnews.com/2017/11/03/insider-selling-edge-therapeutics-inc-edge-insider-sells-7500-shares-of-stock.html.

A number of equities research analysts have weighed in on EDGE shares. BidaskClub upgraded Edge Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, August 3rd. Zacks Investment Research downgraded Edge Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, August 3rd.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in EDGE. Wells Fargo & Company MN increased its holdings in shares of Edge Therapeutics by 1.7% during the first quarter. Wells Fargo & Company MN now owns 11,942 shares of the biotechnology company’s stock valued at $109,000 after acquiring an additional 200 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Edge Therapeutics by 2.9% during the first quarter. Vanguard Group Inc. now owns 700,003 shares of the biotechnology company’s stock valued at $6,377,000 after acquiring an additional 19,973 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Edge Therapeutics by 5.0% during the first quarter. Geode Capital Management LLC now owns 172,646 shares of the biotechnology company’s stock valued at $1,572,000 after acquiring an additional 8,181 shares in the last quarter. Renaissance Technologies LLC bought a new stake in shares of Edge Therapeutics during the first quarter valued at approximately $297,000. Finally, Schwab Charles Investment Management Inc. increased its holdings in shares of Edge Therapeutics by 6.8% during the first quarter. Schwab Charles Investment Management Inc. now owns 74,747 shares of the biotechnology company’s stock valued at $681,000 after acquiring an additional 4,788 shares in the last quarter. Hedge funds and other institutional investors own 49.38% of the company’s stock.

Edge Therapeutics Company Profile

Edge Therapeutics, Inc is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening critical care conditions. The Company’s initial product candidates target rare, acute, life-threatening neurological and other conditions.

Insider Buying and Selling by Quarter for Edge Therapeutics (NASDAQ:EDGE)

Receive News & Ratings for Edge Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edge Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.